BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34404374)

  • 1. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
    Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
    Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma.
    Li W; Yao R; Yu N; Zhang W
    Cancer Biomark; 2024; 40(1):125-139. PubMed ID: 38517778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
    Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
    Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
    Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
    Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
    Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
    BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
    Luo B; Gu YY; Wang XD; Chen G; Peng ZG
    Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma.
    Sun C; Cheng X; Wang C; Wang X; Xia B; Zhang Y
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30393234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
    Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
    Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
    Xiong D; Wei X; Huang W; Zheng J; Feng R
    Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a prognostic metabolic gene signature in diffuse large B-cell lymphoma.
    Wang H; Shao R; Liu W; Tang H; Lu Y
    J Cell Mol Med; 2021 Jul; 25(14):7066-7077. PubMed ID: 34128320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
    Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
    Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation.
    Sun H; Shang J; Liu X; Ren S; Hu S; Wang X
    BMC Cancer; 2024 Apr; 24(1):432. PubMed ID: 38589831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
    He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
    J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.
    Xie W; Wu M; Fu T; Li X; Wang Z; Hu Y; Zhu L; Zhang G
    Gene; 2017 Sep; 627():255-262. PubMed ID: 28629825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.